Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$10.78
0.201.84%
Última actualización: Nov 18, 1:30 PM
Comments
Loading...
Panorámica generalNoticiasBeneficiosOpciones
Calificaciones de analistas
Operaciones de insidersInterés en cortoInforme de acciones
Calificaciones de analistas, precios objetivo, pronóstico
RXO Inc tiene un precio objetivo de consenso de $19.55 basado en las calificaciones de 24 analistas. El máximo es $31, emitido por Wells Fargo el noviembre 11, 2024. El mínimo es $10, emitido por Susquehanna el noviembre 7, 2025. Las 3 calificaciones de analistas más recientes fueron publicadas por Morgan Stanley, UBS y Truist Securities el noviembre 11, 2025, noviembre 7, 2025 y noviembre 7, 2025, respectivamente. Con un precio objetivo promedio de $18 entre Morgan Stanley, UBS y Truist Securities, hay una 67.05% upside implícita para RXO Inc según estas calificaciones más recientes de analistas.
Firmas de analistas que realizan recomendaciones1
Morgan Stanley
UBS
Truist Securities
Barclays
Susquehanna
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para RXO
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/14/2025 | — | Wolfe Research | — | Upgrade | Underperform → Peer Perform | |||
11/11/2025 | 76.33% | Morgan Stanley | → $19 | Upgrade | Equal-Weight → Overweight | |||
11/07/2025 | 39.21% | UBS | $17 → $15 | Maintains | Neutral | |||
11/07/2025 | 85.61% | Truist Securities | $22 → $20 | Maintains | Buy | |||
11/07/2025 | 39.21% | Barclays | $17 → $15 | Maintains | Overweight | |||
11/07/2025 | -7.19% | Susquehanna | $11 → $10 | Maintains | Negative | |||
10/10/2025 | 57.77% | Stifel | $14 → $17 | Maintains | Hold | |||
10/09/2025 | 39.21% | Goldman Sachs | $17 → $15 | Maintains | Neutral | |||
10/08/2025 | 48.49% | JP Morgan | $15 → $16 | Maintains | Underweight | |||
10/03/2025 | 57.77% | UBS | $15 → $17 | Maintains | Neutral | |||
08/12/2025 | 57.77% | Barclays | $18 → $17 | Maintains | Overweight | |||
08/08/2025 | 48.49% | B of A Securities | $18 → $16 | Maintains | Neutral | |||
08/08/2025 | 39.21% | UBS | $14 → $15 | Maintains | Neutral | |||
07/08/2025 | 29.93% | JP Morgan | $15 → $14 | Maintains | Underweight | |||
07/07/2025 | 94.9% | Morgan Stanley | $23 → $21 | Maintains | Equal-Weight | |||
05/21/2025 | 67.05% | Citigroup | $15 → $18 | Maintains | Neutral | |||
05/16/2025 | 67.05% | B of A Securities | $15 → $18 | Maintains | Neutral | |||
05/08/2025 | 29.93% | UBS | $24 → $14 | Maintains | Neutral | |||
05/08/2025 | 67.05% | Goldman Sachs | $21 → $18 | Maintains | Neutral | |||
05/08/2025 | 29.93% | Stifel | $24 → $14 | Maintains | Hold | |||
05/08/2025 | 39.21% | Wells Fargo | $20 → $15 | Maintains | Equal-Weight | |||
04/24/2025 | 76.33% | Truist Securities | $24 → $19 | Maintains | Buy | |||
04/11/2025 | 85.61% | Jefferies | $26 → $20 | Maintains | Buy | |||
04/10/2025 | 94.9% | Goldman Sachs | $24 → $21 | Maintains | Neutral | |||
04/08/2025 | 39.21% | Citigroup | $23 → $15 | Maintains | Neutral | |||
04/04/2025 | — | Oppenheimer | — | Downgrade | Outperform → Perform | |||
04/02/2025 | 104.18% | Barclays | $24 → $22 | Maintains | Overweight | |||
03/27/2025 | 85.61% | Wells Fargo | $22 → $20 | Maintains | Equal-Weight | |||
03/26/2025 | 20.65% | Susquehanna | $18 → $13 | Maintains | Negative | |||
03/13/2025 | 122.74% | Truist Securities | → $24 | Initiates | → Buy | |||
02/06/2025 | 122.74% | Goldman Sachs | $28 → $24 | Maintains | Neutral | |||
02/06/2025 | 122.74% | Stifel | $27 → $24 | Maintains | Hold | |||
02/06/2025 | 132.02% | Morgan Stanley | $27 → $25 | Maintains | Equal-Weight | |||
01/23/2025 | 150.58% | Stifel | $26 → $27 | Maintains | Hold | |||
01/17/2025 | 178.42% | Barclays | $32 → $30 | Maintains | Overweight | |||
01/15/2025 | — | Benchmark | — | Reiterates | Hold → Hold | |||
01/10/2025 | 178.42% | Jefferies | $33 → $30 | Maintains | Buy | |||
01/07/2025 | 159.86% | Wells Fargo | $31 → $28 | Maintains | Equal-Weight | |||
11/18/2024 | 169.14% | Goldman Sachs | → $29 | Reinstates | → Neutral | |||
11/12/2024 | 11.37% | Susquehanna | $16 → $12 | Maintains | Negative | |||
11/12/2024 | 206.26% | Citigroup | $33 → $33 | Downgrade | Buy → Neutral | |||
11/11/2024 | 187.7% | Wells Fargo | → $31 | Reinstates | Equal-Weight → Equal-Weight | |||
10/15/2024 | — | Benchmark | — | Reiterates | → Hold | |||
10/09/2024 | 206.26% | Citigroup | → $33 | Initiates | → Buy | |||
09/26/2024 | 48.49% | Susquehanna | $20 → $16 | Maintains | Negative | |||
09/17/2024 | 187.7% | Oppenheimer | $31 → $31 | Reiterates | Outperform → Outperform | |||
08/15/2024 | 85.61% | Susquehanna | $14 → $20 | Maintains | Negative | |||
08/13/2024 | 187.7% | Jefferies | $33 → $31 | Maintains | Buy | |||
08/13/2024 | — | Benchmark | — | Reiterates | → Hold | |||
08/12/2024 | 141.3% | Morgan Stanley | $19 → $26 | Maintains | Equal-Weight | |||
08/09/2024 | 196.98% | Barclays | $30 → $32 | Maintains | Overweight | |||
08/08/2024 | 159.86% | TD Cowen | $23 → $28 | Maintains | Hold | |||
08/08/2024 | 141.3% | JP Morgan | $25 → $26 | Maintains | Underweight | |||
08/08/2024 | 187.7% | Oppenheimer | $22 → $31 | Maintains | Outperform | |||
08/08/2024 | 187.7% | UBS | $22 → $31 | Maintains | Neutral | |||
07/16/2024 | 178.42% | Barclays | $24 → $30 | Maintains | Overweight | |||
07/09/2024 | 132.02% | JP Morgan | $16 → $25 | Maintains | Underweight | |||
06/12/2024 | — | Benchmark | — | Reiterates | → Hold | |||
05/15/2024 | — | Raymond James | — | Reinstates | → Market Perform | |||
05/06/2024 | 104.18% | Stephens & Co. | $22 → $22 | Reiterates | Equal-Weight → Equal-Weight | |||
04/19/2024 | — | Benchmark | — | Reiterates | → Hold | |||
03/26/2024 | 48.49% | Susquehanna | $15 → $16 | Maintains | Negative | |||
03/25/2024 | 48.49% | Susquehanna | $15 → $16 | Maintains | Negative | |||
02/13/2024 | 104.18% | Oppenheimer | $23 → $22 | Maintains | Outperform | |||
02/09/2024 | 39.21% | Susquehanna | $18 → $15 | Maintains | Negative | |||
02/08/2024 | 104.18% | B of A Securities | $25 → $22 | Downgrade | Buy → Neutral | |||
01/16/2024 | 132.02% | B of A Securities | $21 → $25 | Maintains | Buy | |||
01/10/2024 | 104.18% | Stifel | $20 → $22 | Maintains | Hold | |||
01/10/2024 | 113.46% | Vertical Research | → $23 | Downgrade | Buy → Hold | |||
10/16/2023 | 57.77% | Stifel | $19 → $17 | Maintains | Hold | |||
10/11/2023 | 48.49% | JP Morgan | $17 → $16 | Downgrade | Neutral → Underweight | |||
10/03/2023 | 20.65% | Susquehanna | $14 → $13 | Maintains | Negative | |||
10/02/2023 | 67.05% | Morgan Stanley | $20 → $18 | Maintains | Equal-Weight | |||
08/31/2023 | 29.93% | Susquehanna | $19 → $14 | Downgrade | Neutral → Negative | |||
08/07/2023 | 122.74% | Oppenheimer | → $24 | Reiterates | Outperform → Outperform | |||
08/03/2023 | 85.61% | Morgan Stanley | $20 → $20 | Reiterates | Equal-Weight → Equal-Weight | |||
08/03/2023 | 76.33% | Stephens & Co. | $23 → $19 | Maintains | Equal-Weight | |||
07/12/2023 | 76.33% | Wolfe Research | → $19 | Downgrade | Peer Perform → Underperform | |||
07/06/2023 | 85.61% | Morgan Stanley | $20 → $20 | Reiterates | Equal-Weight → Equal-Weight | |||
06/09/2023 | 85.61% | Susquehanna | → $20 | Initiates | → Neutral | |||
05/24/2023 | 150.58% | Barclays | → $27 | Initiates | → Overweight | |||
05/04/2023 | 94.9% | Wells Fargo | $22 → $21 | Maintains | Equal-Weight | |||
04/04/2023 | — | Benchmark | — | Initiates | → Hold | |||
02/27/2023 | 104.18% | Cowen & Co. | → $22 | Initiates | → Market Perform | |||
02/09/2023 | 113.46% | UBS | $20 → $23 | Maintains | Neutral | |||
02/09/2023 | 104.18% | Goldman Sachs | $20 → $22 | Maintains | Neutral | |||
02/09/2023 | 122.74% | Oppenheimer | $21 → $24 | Maintains | Outperform | |||
02/08/2023 | 85.61% | Stephens & Co. | → $20 | Maintains | Equal-Weight | |||
01/11/2023 | 57.77% | Stifel | $20 → $17 | Downgrade | Buy → Hold | |||
01/09/2023 | 76.33% | JP Morgan | → $19 | Initiates | → Neutral | |||
12/20/2022 | 67.05% | Wells Fargo | → $18 | Initiates | → Equal-Weight | |||
12/09/2022 | 85.61% | UBS | → $20 | Initiates | → Neutral | |||
12/09/2022 | 85.61% | Morgan Stanley | → $20 | Initiates | → Equal-Weight | |||
12/06/2022 | 132.02% | Jefferies | → $25 | Initiates | → Buy | |||
12/05/2022 | — | Raymond James | — | Initiates | → Market Perform | |||
11/30/2022 | 104.18% | B of A Securities | → $22 | Initiates | → Buy | |||
11/22/2022 | 94.9% | Oppenheimer | → $21 | Initiates | → Outperform | |||
11/22/2022 | 85.61% | Goldman Sachs | → $20 | Initiates | → Neutral | |||
11/21/2022 | 150.58% | Vertical Research | → $27 | Initiates | → Buy |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de RXO (RXO)?
El último precio objetivo de RXO (NYSE:RXO) fue comunicado por Wolfe Research el noviembre 14, 2025. La firma de analistas fijó un precio objetivo para $0.00 que espera RXO a fall dentro de 12 meses (un posible -100.00% downside). 38 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre RXO (RXO)?
La última calificación de analistas para RXO (NYSE:RXO) fue proporcionada por Wolfe Research, y RXO mejorado su peer perform calificación.
¿Cuándo se produjo la última revisión al alza de RXO (RXO)?
La última revisión al alza de RXO Inc se produjo en noviembre 14, 2025, cuando Wolfe Research elevó su precio objetivo a N/A. Wolfe Research anteriormente tenía an underperform para RXO Inc.
¿Cuándo fue la última revisión a la baja de RXO (RXO)?
La última revisión a la baja de RXO Inc se produjo en abril 4, 2025, cuando Oppenheimer cambió su precio objetivo de N/A a N/A para RXO Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para RXO (RXO)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de RXO, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de RXO se registró el noviembre 14, 2025, por lo que la próxima calificación estará disponible en torno al noviembre 14, 2026.
¿Es correcta la calificación de los analistas sobre RXO (RXO)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de RXO (RXO) fue un mejorado con un precio objetivo de $0.00 a $0.00. El precio actual al que cotiza RXO (RXO) es de $10.78, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.